| References: |
Endoxifen shows anti-estrogenic effects, and decreases the E2-induced PR expression in MCF-7 cells. Endoxifen also blocks ER-alpha transcriptional activity and inhibits estrogen-induced breast cancer cell proliferation. In MCF7, HS 578T, and BT-549 cells, Endoxifen significantly inhibits cell proliferation. Endoxifen also exhibits four-fold higher inhibition on PKC activity compared to tamoxifen. Endoxifen inhibits the hERG current by preferentially interacting with the activated states of cloned hERG potassium channels with IC50 of 1.6 μM. [5]In vivo, Endoxifen (8 mg/kg, ) inhibits growth of MCF-7 human mammary tumor xenografts in mice, showing more potency than Tamoxifen. For the detailed information of Endoxifen HCl, the solubility of Endoxifen HCl in water, the solubility of Endoxifen HCl in DMSO, the solubility of Endoxifen HCl in PBS buffer, the animal experiment (test) of Endoxifen HCl, the cell expriment (test) of Endoxifen HCl, the in vivo, in vitro and clinical trial test of Endoxifen HCl, the EC50, IC50,and affinity,of Endoxifen HCl, For the detailed information of Endoxifen HCl, the solubility of Endoxifen HCl in water, the solubility of Endoxifen HCl in DMSO, the solubility of Endoxifen HCl in PBS buffer, the animal experiment (test) of Endoxifen HCl, the cell expriment (test) of Endoxifen HCl, the in vivo, in vitro and clinical trial test of Endoxifen HCl, the EC50, IC50,and affinity,of Endoxifen HCl, Please contact DC Chemicals. |
